ProCE Banner Activity

Selection and Sequencing of Targeted Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer

Slideset Download
Download these slides from an expert-led symposium for the most recent data on the selection and sequencing of targeted therapy for HR-positive/HER2-negative metastatic breast cancer.

Released: June 07, 2022

Expiration: June 06, 2023

No longer available for credit.

Share

Faculty

Komal Jhaveri

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Lilly

Novartis Pharmaceuticals Corporation

Sanofi Genzyme

Program Director Disclosure

Program Director

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Komal Jhaveri, MD, FACP, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Biotheranostics, Blueprint Medicines, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Genentech, Jounce Therapeutics, Lilly, Novartis, Pfizer, Seattle Genetics, SunPharma, and Taiho Oncology and funds for research support paid to her institution from ADC Therapeutics, AstraZeneca, Clovis Oncology, Debio, Genentech, Immunomedics/Gilead, Lilly, Merck/VelosBio, Novartis, Novita Pharmaceuticals, Pfizer, Puma, and Zymeworks.